Cue Biopharma Inc’s recent filing unveils that its Director Sarraf Pasha acquired Company’s shares for reported $99747.0 on Dec 30 ’25. In the deal valued at $0.31 per share,323,857 shares were bought. As a result of this transaction, Sarraf Pasha now holds 323,857 shares worth roughly $0.11 million.
Then, MATTEO GIACOMO LEVISETTI bought 7,230 shares, generating $1,907 in total proceeds.
Jefferies initiated its Cue Biopharma Inc [CUE] rating to a Buy in a research note published on March 13, 2024; the price target was $6. Piper Sandler began covering CUE with “an Overweight” recommendation on November 21, 2022. H.C. Wainwright started covering the stock on January 13, 2022. It rated CUE as “a Buy”.
Price Performance Review of CUE
On Monday, Cue Biopharma Inc [NASDAQ:CUE] saw its stock fall -4.30% to $0.34. Over the last five days, the stock has lost -9.83%. Cue Biopharma Inc shares have fallen nearly -76.21% since the year began. Nevertheless, the stocks have risen 12.97% over the past one year.
How much short interest is there in Cue Biopharma Inc?
A steep rise in short interest was recorded in Cue Biopharma Inc stocks on 2025-12-31, growing by 1.0 million shares to a total of 1.44 million shares. Yahoo Finance data shows the prior-month short interest on 2025-11-28 was 0.44 million shares. There was a rise of 69.33%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on January 03, 2022 when Craig Hallum began covering the stock and recommended ‘”a Buy”‘ rating along with a $28 price target.
